Degrees of freedom of TaaTP [Power / Sample Size]

posted by d_labes  – Berlin, Germany, 2019-05-14 16:01 (505 d 04:53 ago) – Posting: # 20282
Views: 3,618

(edited by d_labes on 2019-05-14 16:21)

Dear Helmut, dear Olivbood,

» ...
» » Furthermore, while the two parts of the trial will be evaluated as incomplete block designs, it seems to me that the original sequences and periods are preserved (e.g. an observation from period 3 is still coded as period 3), so that the degree of freedom would not be the same as for the conventional 2x2x2 crossover, no?
» Correct. Has some strange side-effects (see there).

To repeat the recommendation in this post:
The degrees of freedom are different for the 2x2 design and the design of the TaaTP.
We can mimic the df's, at least approximately, if we use the robust df's.

(TaaTP: Two-at-a-Time Principle)

But makes seldom a difference worth thinkin' about:
sampleN.TOST(CV=0.3, design="2x2x2", targetpower=0.9, print=FALSE)
  Design alpha  CV theta0 theta1 theta2 Sample size Achieved power Target power
1  2x2x2  0.05 0.3   0.95    0.8   1.25          52      0.9019652          0.9
sampleN.TOST(CV=0.3, design="3x6x3", targetpower=0.9, robust=TRUE, print=FALSE)
  Design alpha  CV theta0 theta1 theta2 Sample size Achieved power Target power
1  3x6x3  0.05 0.3   0.95    0.8   1.25          54      0.9112411          0.9

2 subjects more but due to balanced design, i.e. sample size has to be a multiple of 6.
If we go for an unbalanced design we have also a power of 90% with 52 subjects:
power.TOST(CV=0.3, design="3x6x3", robust=TRUE, n=52)
Unbalanced design. n(i)=9/9/9/9/8/8 assumed.
[1] 0.9005174



Complete thread:

 Admin contact
21,090 posts in 4,398 threads, 1,469 registered users;
online 16 (1 registered, 15 guests [including 3 identified bots]).
Forum time: Wednesday 20:54 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz